USCB vs CARE
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 29, 2026
USCB
51.5
AI Score
VS
CARE Wins
CARE
68.5
AI Score
Investment Advisor Scores
CARE
69score
Recommendation
BUY
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | USCB | CARE | Winner |
|---|---|---|---|
| Net Income | 18.43M | 31.36M | CARE |
| ROE | 7.9% | 7.5% | USCB |
| ROA | 0.6% | 0.6% | CARE |
| Total Assets | 3.02B | 4.85B | CARE |
| Cash | 118.15M | 105.16M | USCB |
| Free Cash Flow | 39.16M | 31.81M | USCB |
Relative Price Performance (Last 90 Days)
USCB 1M: +2.7%
· 3M: +20.9%
CARE 1M: -7.8%
· 3M: +15.3%
Current Technical Phase
USCB
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (7.3% over 20 days), RSI 58
CARE
NeutralHold
Mixed signals - no dominant trend phase, RSI 44
Fundamentals Snapshot
| Metric | USCB | CARE |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.6 | 12.1 |
| Trailing P/E | 14.3 | 5.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.7% |
| Gross Margin | 1.0% | 1.0% |
| Operating Margin | 0.5% | 0.6% |
| EPS | 1.56 | 5.80 |
| Dividend Yield | 0.02% | 0.00% |
Frequently Asked Questions
Based on our detailed analysis, CARE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.